Clinical Trial

IKS014 in Advanced Solid Tumors That Express HER2

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09 -> 2026-12 2026-05-09
minor Completion pushed: 2027-09 -> 2027-12 2026-05-09
Trial Details
NCT Number NCT05872295
Lead Sponsor Iksuda Therapeutics Ltd.
Conditions Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Enrollment 165 participants
Start Date 2023-09-14
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08